|
|
|
|
|
|
|
|
|
|
abstract
Abstract
MRI
and FDG PET-CT play central and complementary roles in gynecologic
cancer care. Because treatment often requires combinations of surgery,
radio- and chemotherapy, imaging is central to triage and to determine
prognosis. This article reviews the use of the two imaging modalities in
the initial evaluation of the common cancers --- uterine cervical,
uterine endometrial and epithelial ovarian cancers. Imaging features
that impact on management and the relative strengths and weaknesses of
the two modalities are highlighted. Use of imaging after initial therapy
to assess for recurrence and to plan salvage therapy is described.
Newer functional and molecular techniques in MRI and PET are evaluated.
Finally, we describe our initial experience with PET-MRI, an emerging
technology that may prove to be a mainstay in personalized gynecologic
cancer care and adaptive therapy.
Copyright © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Copyright © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.